Key Takeaway
Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee saysGet our breaking news email, free app or daily news podcastThe federal government should fund treatment for thousands of women with breast cancer or endometriosis, and children with gender dysphoria, according to the Pharmaceutical Benefits Scheme’s advisory committee. The committee met urgently in July in…
Published August 18, 2026 · Category: News
Overview
Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee says
The federal government should fund treatment for thousands of women with breast cancer or endometriosis, and children with gender dysphoria, according to the Pharmaceutical Benefits Scheme’s advisory committee.
Details
The committee met urgently in July in response to AstraZeneca’s announcement it would remove Zoladex from the market, risking leaving more than 7,500 women with breast cancer without an alternative treatment.
Continue reading...
Source
Originally published at www.theguardian.com.
Related Articles
Frequently Asked Questions
What is "PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend" about?+
Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee saysGet our breaking news email, free app or daily news podcastThe federal government should fund treatment for thousands of women with breast cancer or endometriosis, and children with gender dysphoria, according to the Pharmaceutical Benefits Scheme’s advisory committee.The committee met urgently in July in response to AstraZeneca’s announcement it would remove Zoladex
Who reported this story?+
This story was reported by The Guardian World.